What MTPConnect does

MTPConnect, now operating as AUScelerate, is an Australian not-for-profit medical research investor and accelerator founded in 2015 and headquartered in Brighton, with program presence in Adelaide and Western Australia. The organisation channels government and regional development capital into early-stage Australian life sciences companies, having deployed A$12.07 million of Medical Research Future Fund (MRFF) capital into 14 startups developing medical devices and drugs spanning cardiovascular disease, diabetes and other conditions. Its active program portfolio includes the Targeted Translation Research Accelerator (TTRA) Drugs & Devices, the TTRA for Diabetes and Cardiovascular Disease, the Australian Antimicrobial Resistance Network (AAMRNet), the Investor Ready Program, the AMMA Pathway to Market, the Adelaide Intermediary Program, the WA Hub, AUSCEP, WAGES, and the SABRE Alliance, alongside completed initiatives such as the Clinical Translation and Commercialisation Medtech Program (CTCM), BioMedTech Horizons, the Biomedical Translation Bridge, the Biomedical AI Sprints Accelerator and the REDI initiative.

The organisation operates a sales-led, intermediary-driven go-to-market model, providing one-on-one advisory meetings, strategic connections, commercialisation workshops, sector reports and case-study publishing (via LinkedIn, podcast, newsletter and YouTube channels). It serves as an Industry Partner Organisation for Australia's federal Industry Growth Program, supporting hundreds of life sciences SMEs, and partners with state-level agencies such as the Adelaide Economic Development Agency (AEDA), through which it secured A$3.6 million under the 2025/26 Strategic Partnerships Program. There is no public pricing model: services are grant-funded rather than commercially priced, and revenue is not disclosed.

Beneficiaries and portfolio companies include Ventora Medical, Endo Axiom, CathRx, LISTEN and Western Sydney University (developer of the APHLID mental health app). In 2025 the organisation rebranded from MTPConnect to AUScelerate to better signal its mission connecting capability, capital and commercial pathways across Australia and globally. It employs between 11 and 50 staff and is led by CFO/Company Secretary Hamish George.

Name

MTPConnect

Legal name

MTPConnect

Website

https://mtpconnect.org.au

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

MTPConnect (now AUScelerate) is an Australian not-for-profit accelerator founded in 2015 that deploys government grant capital, principally from the MRFF and AEDA, into early-stage startups and SMEs developing medical devices, drugs, and digital health technologies.

Ownership category

akta.pro rank

Product category

Life Sciences Commercialization and Accelerator Services

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Medication Therapy Management (MTM) & Adherence Programs (HLAEAKAH)

akta.pro secondary industries

Medication Adherence & Therapy Management Platforms (refills, reminders, MTM) (HLALAIAG), Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools (HLACAKAH)

Keywords

• Life sciences accelerator
• Medical research investment
• Biomedical commercialization
• Medtech innovation programs
• Healthcare startup funding

Headquarters

HQ city

Brighton

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Government Funded Investment Programs: MTPConnect is a not-for-profit organization that receives funding from the Australian government's Medical Research Future Fund (MRFF) to invest in medical research and life sciences innovation. It deploys capital through grant programs to startups and SMEs developing medical devices and drugs.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

MTPConnect (now operating as AUScelerate) is a not-for-profit medical research investor and accelerator organization that deploys government-backed grant funding and commercialization support programs to Australian startups and SMEs developing medical devices, drugs, and digital health innovations. It runs multiple accelerator programs (TTRA, AAMRNet, Investor Ready, AMMA Pathway to Market, IGP Industry Partner, Adelaide Intermediary, WA Hub, WAGES, AUSCEP, SABRE Alliance) that provide intermediary services, strategic connections, workshops, and advisory support to translate research into market-ready products.

Product overview

AUScelerate (formerly MTPConnect) is a not-for-profit medical research investor and accelerator organization that supports Australian life sciences innovation through multiple commercialisation support programs. The organization operates a portfolio of active programs including the Targeted Translation Research Accelerator (TTRA) for Drugs & Devices focusing on cardiovascular disease and diabetes, the Australian Antimicrobial Resistance Network (AAMRNet), the Investor Ready Program, AMMA Pathway to Market, and serves as Industry Partner Organisation for Australia's Industry Growth Program. The organization recently rebranded from MTPConnect to AUScelerate to better reflect its mission. It has invested $12.07 million into 14 Australian startups working on medical devices and drugs through MRFF funding, and administers regional hubs in Adelaide and Western Australia.

Differentiator

Problem solved

Functional benefit

Brands

• AUScelerate: The new name and brand identity adopted by MTPConnect to better reflect its mission supporting Australia's life sciences ecosystem and connecting capability, capital and commercial pathways globally.

Products and services

• TTRA Drugs & Devices Flagship accelerator program funding Australian startups developing medical devices and drugs, with a primary focus on cardiovascular disease and diabetes treatments. Part of the $12.07 million MRFF-funded investment into 14 Australian startups.
• Targeted Translation Research Accelerator (TTRA) for Diabetes and Cardiovascular Disease Specialized accelerator program focused on translating research innovations for diabetes and cardiovascular disease into commercial applications, supporting Australian researchers and startups in these therapeutic areas.
• Australian Antimicrobial Resistance Network (AAMRNet) Network initiative addressing antimicrobial resistance challenges in Australia, connecting researchers, industry stakeholders, and policymakers to coordinate AMR response and innovation.
• Investor Ready Program Program designed to prepare Australian life sciences companies for investment by strengthening commercial capability, providing tailored one-on-one intermediary service meetings, and facilitating strategic connections with investors and partners.
• AMMA Pathway to Market Program supporting Australian medtech companies in bringing products to market, showcased at industry events including the AMMA Medtech Showcase in Melbourne.
• Industry Growth Program (IGP) Industry Partner Organisation service Tailored commercialization support delivered as Industry Partner Organisation for Australia's Industry Growth Program, including one-on-one intermediary service meetings, strategic connections, commercialisation-focused workshops and events, sector updates and reports, and ongoing advisory support to life sciences SMEs and startups.
• Adelaide Intermediary Program Regional intermediary program supporting life sciences innovation and commercialization in Adelaide, delivered as part of the AEDA Strategic Partnerships Program.
• WA Hub Western Australia regional hub providing life sciences innovation support and commercialisation services to WA-based startups and SMEs.
• WAGES Active initiative listed among current AUScelerate programs supporting Australian life sciences innovation.
• AUSCEP Australian accelerator program supporting life sciences innovation through commercialization pathways.
• SABRE Alliance Strategic alliance supporting biomedical and medtech development in Australia.
• Clinical Translation and Commercialisation Medtech Program (CTCM) Completed accelerator program that supported clinical translation and commercialisation of medtech innovations in Australia.
• BioMedTech Horizons Program Completed accelerator program supporting biomedical and medtech horizons innovation in Australia.
• Biomedical Translation Bridge Program Completed program bridging biomedical research to translation and commercialisation for Australian life sciences researchers.
• Researcher Exchange and Development within Industry (REDI) initiative Completed initiative supporting researcher exchange and development within the Australian life sciences industry.
• Biomedical AI Sprints Accelerator Completed accelerator program focused on biomedical AI innovations in Australia.
• MTPConnect Podcast Ongoing podcast platform showcasing Australian medtech and life sciences innovations, featuring company interviews, medtech showcase episodes (e.g., 'Better Health Made Here' covering Arelis, 4D Medical, Lenexa Medical, Akeeko Medical), and sector updates.

Quantifiable outcome

• 160 jobs created, 53,000+ delegates attracted, $300 million economic injection, 50+ new businesses launched (via AEDA program)

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered minor and core.

• Renew AdelaideminorStrategic or Co-development PartnerOne of six funded partners in AEDA's Strategic Partnerships Program, focused on startup development initiatives.
• Business Events AdelaideminorStrategic or Co-development PartnerOne of six funded partners in AEDA's Strategic Partnerships Program, focused on business events.
• University of Adelaide's ThincLabminorStrategic or Co-development PartnerOne of six funded partners in AEDA's Strategic Partnerships Program, focused on startup incubation.
• Festival City AdelaideminorStrategic or Co-development PartnerOne of six funded partners in AEDA's Strategic Partnerships Program, focused on festival events.
• Study AdelaideminorStrategic or Co-development PartnerOne of six funded partners in AEDA's Strategic Partnerships Program, focused on international education.
• Australian Industry Growth Program (IGP)coreStrategic or Co-development PartnerAUScelerate supports Australia's Industry Growth Program as an Industry Partner Organisation, providing tailored support including intermediary services, strategic connections, workshops, events, sector updates, reports, and advisory support to life sciences SMEs.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• JLABS (Johnson & Johnson Innovation): Johnson & Johnson's life sciences incubator network providing lab space, mentorship, and capital to early-stage biotech and medtech startups globally. Comparable to MTPConnect as a life sciences accelerator serving early-stage companies, though JLABS is corporate-backed and global in scope.
• CSIRO (Commonwealth Scientific and Industrial Research Organisation): Australia's national science agency funding and conducting health and biosecurity research. Operates overlapping mission in supporting Australian science commercialization, though at much broader scale.

Direct peers

• IndieBio: Biotech-focused accelerator program that provides seed funding, lab space, and mentorship to early-stage biology startups. Directly comparable to MTPConnect's accelerator model for life sciences companies, though for-profit and US-based.
• Biolabs: Global life sciences co-working and accelerator operator with shared lab facilities and programming for biotech startups. Closely matches MTPConnect's model of supporting early-stage life sciences companies with commercialization and infrastructure resources.
• Creative Destruction Lab: Science-based accelerator with dedicated Biomedical Engineering stream providing mentorship and goal-setting programming to early-stage ventures. Comparable objective-based seed accelerator model applied to life sciences ventures.
• MassChallenge: Global non-equity accelerator running health-focused cohorts supporting early-stage startups with mentorship and programming. Directly comparable to MTPConnect's non-equity, life sciences commercialization support model.
• ANDHealth: Australia's only dedicated digital health accelerator providing commercialization support to health technology SMEs. Direct peer serving overlapping Australian digital health and life sciences founder community.

Regional players

• Cicada Innovations: Australian deep tech incubator supporting science-based startups with lab facilities, mentorship, and commercialization support. Regional peer operating in adjacent Australian deep tech/life sciences ecosystem.
• Stone & Chalk: Australian innovation hub supporting emerging technology startups across multiple sectors including healthtech. Comparable regional commercialization support function for Australian startups.
• NSW Health Medical Research Support Program: State-level government program funding medical research and commercialization in NSW. Comparable government-funded mechanism for supporting life sciences research translation in Australia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@auscelerate
• LinkedInlinkedin.com/company/auscelerate
• Xx.com/mtpconnect_aus

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments23 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MTPConnect